The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Molecular therapies for HCC: Looking outside the box
Open accessAbstract
Over the past decade, sorafenib has been the only systemic agent with proven clinical efficacy for patients with unresectable hepatocellular carcinoma (HCC). Recently, lenvatinib was shown to be non-inferior to sorafenib, while regorafenib, cabozantinib, and ramucirumab were shown to be superior to placebo in patients failing sorafenib. In addition, trials of immune checkpoint inhibitors reported encouraging efficacy signals. However, apart from alpha-fetoprotein, which is used to select patients for ramucirumab, no biomarkers are available to identify patients that may respond to a specific treatment. Different synergisms have been postulated based on the potential interplay between antiangiogenic drugs and immunotherapy, with several clinical trials currently testing this hypothesis. Indeed, encouraging preliminary results of phase I studies of bevacizumab plus atezolizumab and lenvatinib plus pembrolizumab have led to the design of ongoing phase III trials, including both antiangiogenics and immune checkpoint inhibitors in the front-line setting. Other important phase II studies have tested molecular therapies directed against different novel targets, such as transforming growth factor-beta, MET (hepatocyte growth factor receptor), and fibroblast growth factor receptor 4. These studies integrated translational research with the aim of better defining the biological tumour profile and identifying tumour and blood biomarkers that select patients who may really benefit from a specific molecular therapy. Importantly, good safety profiles make these drugs suitable for future combinations. In this review, we discuss the most recent data on novel combination strategies and targets, as well as looking ahead to the future role of molecular therapies in the treatment of patients with advanced HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Self-citationZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Self-citationCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Self-citationNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Self-citationZhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Self-citationIdentification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
The roles of TGFβ in the tumour microenvironment
Pickup, M., Novitskiy, S., & Moses, H. L. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3603 · Cited by 917
Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
Yau, T., Park, J. W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Han, K.-H., Harding, J. J., Merle, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.029 · Cited by 647
Self-citationTargeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 611
Self-citationPlasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Invasive growth: a MET-driven genetic programme for cancer and stem cells
Boccaccio, C., & Comoglio, P. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1912 · Cited by 538
Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494
Kato, Y., Tabata, K., Kimura, T., Yachie-Kinoshita, A., Ozawa, Y., Yamada, K., Ito, J., Tachino, S., Hori, Y., Matsuki, M., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212513 · Cited by 460
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406
Rimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Porta, C., Daniele, B., Bolondi, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30146-3 · Cited by 351
Self-citationHagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., Bifulco, N., Kim, J. L., Hodous, B., Brooijmans, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1029 · Cited by 313
Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita, H., & Nakajima, Y. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12069 · Cited by 276
Liu, X., Wang, Q., Yang, G., Marando, C., Koblish, H. K., Hall, L. M., Fridman, J. S., Behshad, E., Wynn, R., Li, Y., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1157 · Cited by 265
Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
Bouattour, M., Raymond, E., Qin, S., Cheng, A., Stammberger, U., Locatelli, G., & Faivre, S. (2018) · Hepatology · doi:10.1002/hep.29496 · Cited by 257
Self-citationChen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., Zhou, S., Liang, Y., Huang, D., Liang, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.019 · Cited by 251
Kelley, R. K., Gane, E., Assenat, E., Siebler, J., Galle, P. R., Merle, P., Hourmand, I. O., Cleverly, A., Zhao, Y., Gueorguieva, I., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000056 · Cited by 247
Self-citationFizazi, K., Maillard, A., Penel, N., Baciarello, G., Allouache, D., Daugaard, G., Van de Wouw, A., Soler, G., Vauleon, E., Chaigneau, L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394 · Cited by 246
Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma
Nault, J., Martin, Y., Caruso, S., Hirsch, T. Z., Bayard, Q., Calderaro, J., Charpy, C., Copie‐Bergman, C., Ziol, M., Bioulac‐Sage, P., et al. (2020) · Hepatology · doi:10.1002/hep.30811 · Cited by 207
Self-citationManning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H.-Y., Breder, V. V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4004 · Cited by 205
Self-citationMiura, S., Mitsuhashi, N., Shimizu, H., Kimura, F., Yoshidome, H., Otsuka, M., Kato, A., Shida, T., Okamura, D., & Miyazaki, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-56 · Cited by 193
Kwilas, A. R., Ardiani, A., Donahue, R. N., Aftab, D. T., & Hodge, J. W. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0294-y · Cited by 192
Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23795 · Cited by 187
Novel TGF-β inhibitors ready for prime time in onco-immunology
de Gramont, A., Faivre, S., & Raymond, E. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1257453 · Cited by 183
Self-citationFGF19–FGFR4 Signaling in Hepatocellular Carcinoma
Raja, A., Park, I., Haq, F. U., & Ahn, S. (2019) · Cells · doi:10.3390/cells8060536 · Cited by 173
Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy
Rivera, L. B., Meyronet, D., Hervieu, V., Frederick, M. J., Bergsland, E. K., & Bergers, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.055 · Cited by 151
Faivre, S. J., Santoro, A., Kelley, R. K., Gane, E. J., Costentin, C. E., Gueorguieva, I., Smith, C. L., Cleverly, A., Lahn, M., Raymond, É., et al. (2019) · Liver International · doi:10.1111/liv.14113 · Cited by 149
Self-citationEMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Bladt, F., Faden, B., Friese‐Hamim, M., Knuehl, C., Wilm, C., Fittschen, C., Grädler, U., Meyring, M., Dorsch, D., Jaehrling, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3247 · Cited by 140
Ikeda, M., Sung, M. W., Kudo, M., Kobayashi, M., Baron, A. D., Finn, R. S., Kaneko, S., Zhu, A. X., Kubota, T., Kraljevic, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4076 · Cited by 125
Self-citationModulation of Immunity by Antiangiogenic Molecules in Cancer
Terme, M., Colussi, O., Marcheteau, E., Tanchot, C., Tartour, É., & Taïeb, J. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/492920 · Cited by 122
Sakai, D., Kanai, M., Kobayashi, S., Eguchi, H., Baba, H., Seo, S., Taketomi, A., Takayama, T., Yamaue, H., Ishioka, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy282 · Cited by 112
Llovet, J. M., Kudo, M., Cheng, A., Finn, R. S., Galle, P. R., Kaneko, S., Meyer, T., Qin, S., Dutcus, C. E., Chen, E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps4152 · Cited by 112
Self-citationStein, S., Pishvaian, M. J., Lee, M. S., Lee, K.-H., Hernandez, S., Kwan, A., Liu, B., Grossman, W., Iizuka, K., & Ryoo, B. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4074 · Cited by 111
Hyeon, J., Ahn, S., Lee, J. J., Song, D. H., & Park, C.-K. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2609-x · Cited by 103
Pishvaian, M. J., Lee, M. S., Ryoo, B., Stein, S., Lee, K. H., Verret, W. J., Spahn, J. H., Shao, H., Liu, B., Iizuka, K., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.028 · Cited by 76
Mantovani, S., Oliviero, B., Varchetta, S., Mele, D., & Mondelli, M. U. (2020) · Cancers · doi:10.3390/cancers12040926 · Cited by 71
Pascut, D., Pratama, M. Y., Võ, N. V. T., Masadah, R., & Tiribelli, C. (2020) · Cancers · doi:10.3390/cancers12040823 · Cited by 66
New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
Mossenta, M., Busato, D., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Cancers · doi:10.3390/cancers11081086 · Cited by 56
Ikeda, M., Morimoto, M., Tajimi, M., Inoue, K., Benhadji, K. A., Lahn, M. M. F., & Sakai, D. (2019) · Investigational New Drugs · doi:10.1007/s10637-018-0636-3 · Cited by 46
Nishida, N., & Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051274 · Cited by 40
Huang, J., Qiu, M., Wan, L., Wang, G., Huang, T., Chen, Z., Jiang, S., Li, X., Xie, L., & Cai, L. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487737 · Cited by 37
Kelley, R. K., Cheng, A., Braiteh, F. S., Park, J., Benzaghou, F., Milwee, S., Borgman, A. E., El-Khoueiry, A. B., Kayali, Z. K., Zhu, A. X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps4157 · Cited by 33
Self-citationKaseb, A. O., Duda, D. G., Cao, H. S. T., Abugabal, Y. I., Vence, L. M., Rashid, A., Pestana, R. C., Blando, J. M., Singh, S., Vauthey, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.486 · Cited by 29
Gao, L., Shay, C., Lv, F., Wang, X., & Teng, Y. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0354-4 · Cited by 27
Finn, R. S., Kudo, M., Cheng, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy269.057 · Cited by 27
Self-citationTransforming Growth Factor-β Drives the Transendothelial Migration of Hepatocellular Carcinoma Cells
Koudelková, P., Costina, V., Weber, G., Dooley, S., Findeisen, P., Winter, P., Agarwal, R., Schlangen, K., & Mikulits, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102119 · Cited by 19
Esteban-Fabró, R., Bassaganyas, L., Torrecilla, S., Moeini, A., Franch‐Expósito, S., Vila-Casadesús, M., Nadeu, F., Sia, D., Salaverría, I., Cabellos, L., et al. (2019) · Clinical Research (Excluding Clinical Trials) · doi:10.1158/1538-7445.sabcs18-3095 · Cited by 1
Cited by
Finn, R. S., Ikeda, M., Zhu, A. X., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00808 · Cited by 1,167
Self-citationEvolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
Feng, J., Li, J., Wu, L., Yu, Q., Ji, J., Wu, J., Dai, W., & Guo, C. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01629-4 · Cited by 699
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Piñero, F., Dirchwolf, M., & Pessôa, M. G. (2020) · Cells · doi:10.3390/cells9061370 · Cited by 498
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
Li, Z.-J., Dai, H.-Q., Huang, X.-W., Feng, J., Deng, J.-H., Wang, Z.-X., Yang, X.-M., Liu, Y.-J., Wu, Y., Chen, P.-H., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0478-3 · Cited by 315
Metadata
- Authors
- Faivre, S., Rimassa, L., & Finn, R. S.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 72
- Issue
- 2
- Pages
- 342-352
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2998980069
- Cited by
- 326
- References
- 63
- FWCI
- 31.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.